Skip to main content

Biogen says its new Alzheimer's drug slows cognitive decline in late-stage study

A global study of Biogen Inc.'s new drug, lecanemab, showed statistically significant improvement in slowing the cognitive effects of Alzheimer's disease compared to a placebo, the company said.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.